Zoetis Investors Have Deadline to Lead Securities Fraud Lawsuit

A lead plaintiff can represent the class and help guide the litigation, making the selection of experienced counsel crucial for investors.

Rosen Law Firm is notifying purchasers of Zoetis Inc. (NYSE: ZTS) securities who bought between January 14, 2025, and May 6, 2026, of the critical July 27, 2026 deadline to move the Court to serve as lead plaintiff in a class action lawsuit. Investors who purchased Zoetis securities during the class period may be entitled to compensation without out-of-pocket expenses through a contingency fee arrangement.

The lawsuit alleges that Zoetis made false or misleading statements and failed to disclose that veterinarian prescription growth and adoption of its Librela canine pain treatment were weakening due to FDA safety warnings. It further claims that Zoetis' Simparica Trio lost significant market share to a lower-priced competitor and that its dermatology products, Apoquel and Cytopoint, experienced substantial market share loss to a newly launched competing canine treatment.

Rosen Law Firm, which specializes in securities class actions and shareholder derivative litigation, has a history of recovering substantial amounts for investors. The firm urges investors to select counsel with a proven track record in leadership roles.

A class action has already been filed. Interested investors can join the action or obtain more information by visiting the Rosen Law Firm website or contacting the firm. No class has yet been certified, and investors have the right to choose their own counsel or remain as absent class members.